In the last trading session, 1.45 million shares of the Prime Medicine Inc (NASDAQ:PRME) were traded, and its beta was 1.90. Most recently the company’s share price was $1.57, and it changed around -$0.11 or -6.55% from the last close, which brings the market valuation of the company to $205.92M. PRME currently trades at a discount to its 52-week high of $8.27, offering almost -426.75% off that amount. The share price’s 52-week low was $1.12, which indicates that the current value has risen by an impressive 28.66% since then.
Prime Medicine Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.18. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended PRME as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Prime Medicine Inc is expected to report earnings per share of -0.31 for the current quarter.
Prime Medicine Inc (NASDAQ:PRME) trade information
Instantly PRME has showed a red trend with a performance of -6.55% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.8300 on recent trading dayincreased the stock’s daily price by 14.21%. The company’s shares are currently down -46.23% year-to-date, but still down -5.42% over the last five days. On the other hand, Prime Medicine Inc (NASDAQ:PRME) is -2.48% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $17, which translates to bulls needing to increase their stock price by 90.76% from its current value. Analyst projections state that PRME is forecast to be at a low of $12 and a high of $23.
Prime Medicine Inc (PRME) estimates and forecasts
The year-over-year growth rate is expected to be 560.21%, up from the previous year.
Consensus estimates provided by 9 financial analysts predict the company will bring in an average of 3.43M in revenue for the current quarter. 9 analysts expect Prime Medicine Inc to make 3.39M in revenue for the current ending quarter. Analysts predict that the company’s current quarter sales will jump, forecast at 480.77%. Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -124.13%. Prime Medicine Inc earnings are expected to increase by 27.67% in 2025, but the outlook is positive 12.59% per year for the next five years.
PRME Dividends
Prime Medicine Inc’s next quarterly earnings report is expected to be released in June.
ARK INVESTMENT MANAGEMENT LLC, with 5.1404% or 6.13 million shares worth $31.49 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
ARK ETF Trust-ARK Genomic Revolution ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 2.5 shares worth $3.92 million, making up 1.91% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund held roughly 2.1 shares worth around $3.29 million, which represents about 1.60% of the total shares outstanding.
